Lyell Immunopharma, Inc. (LYEL) › Operating Cash FlowLyell Immunopharma, Inc. (LYEL) — Operating Cash FlowAnnual figures by fiscal year, from SEC filings.2019: $39.47M2020: -$160.87M2021: -$126.25M2022: -$169.56M2023: -$163.69M2024: -$162.39M2025: -$150.02M-$150.02M2019Operating Cash Flow (USD)2025Fiscal YearOperating Cash FlowChange YoY2025-$150.02M+7.6%2024-$162.39M+0.8%2023-$163.69M+3.5%2022-$169.56M-34.3%2021-$126.25M+21.5%2020-$160.87M-507.5%2019$39.47M—Other metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityCash & EquivalentsCapital ExpendituresShares OutstandingDividends Per Share